Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 studyAnthony R. Mato, Michael Wang, Nirav N. Shah et al.|The Lancet|2021Cited by 456
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignanciesTania Jain, Sham Mailankody, Andrea Knežević et al.|Blood Advances|2020Cited by 264
Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström MacroglobulinemiaSteven P. Treon, Jorge J. Castillo, Kirsten Meid et al.|Journal of Clinical Oncology|2020Cited by 150
Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemiaLian Xu, Steven P. Treon, Nicholas Tsakmaklis et al.|Blood|2017Cited by 138
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL studyFranck Morschhauser, Loretta J. Nastoupil, James Lymp et al.|Nature Medicine|2024Cited by 127